NRS
Heather Brosius, RN, CPN
Geisinger Medical Center
Mary Hendry, RN, MS
Jefferson Adult CF Center
Life expectancy has grown exponentially in the past five years, particularly with the FDA approval and release of elexacaftor-tezacaftor-ivacaftor (ETI) in November 2019. Increased longevity is a wonderful ‘problem’ to have, but it comes with new complications not previously focused on for most persons with cystic fibrosis. Familial diseases that surface with aging had previously been non-significant with a shortened life span, and retirement planning was not a focus for most persons impacted by CF lung and GI disease presentations. Diet had been focused more on calorie maximizing and less on healthy eating. So much has changed, and like a fine wine, aging needs to be focused on optimizing conditions and preventing factors that can spoil quality.
Speaker: Mary A. Jones-Gant, MSN, NP-C (she/her/hers) – ChristianaCare
Speaker: Kelly Muldowney, BA (she/her/hers) – Cystic Fibrosis Foundation
Speaker: Lauren N. Kormelink, PharmD, BCACP (she/her/hers) – University of Kentucky HealthCare, University of Kentucky College of Pharmacy
Community Speaker: Paul R. McCormick, JD MPA EdD (he/him/his) – Magnet School
Community Speaker: Jess McCormick